Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03325556 · ClinicalTrials.gov registry record · Phase 3
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 392
- Enrollment target
NCT03325556 is a Phase 3 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 392 participants.
The verdict
NCT03325556, a Phase 3 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 392 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label pimavanserin treatment.
Interventions
- DRUG Placebo
- DRUG Pimavanserin 34 mg
- DRUG Pimavanserin 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2017-09-27 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03325556
The ClinicalTrials.gov registry entry for NCT03325556 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 392 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03325556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03325556 about?
NCT03325556 is a clinical study titled "Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis". The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label pimavanserin treatment.
What is the current status of trial NCT03325556?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 392 participants. The study started on 2017-09-27. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT03325556?
The interventions under investigation include: Placebo (DRUG), Pimavanserin 34 mg (DRUG), Pimavanserin 20 mg (DRUG).
Who is sponsoring clinical trial NCT03325556?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.